---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033652"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:33:03.290700+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcadia begins strategic review, reports $18.8M cash and Q2 revenue guidance of $1.3-1.5M

## Summary
- Strategic review initiated; Lake Street Capital Markets as advisor; options include sale, merger, or other transactions.
- Cash and cash equivalents of $18.8M as of June 30, 2023; Q2 revenue expected between $1.3M and $1.5M.
- Exiting ProVault and SoulSpring body care brands, saving $3-4M annually starting August 2023.
- Expanded GoodWheat portfolio with launch of pancake mixes; Q2 results to be announced August 10, 2023.

## SEC filing metadata
- accession: 0000950170-23-033652
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017023033652/0000950170-23-033652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017023033652/rkda-20230720.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033652
- JSON: https://secwatch.observer/filing/0000950170-23-033652.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033652.txt

## Key facts
- Earnings Releases
  Arcadia Biosciences, Inc. reported the second quarter of 2023 results: revenue $1.3 million - $1.5 million.
  - Period: the second quarter of 2023
  - Revenue: $1.3 million - $1.5 million
  - Result: preliminary results
  source text: As of June 30, 2023, Arcadia Biosciences had approximately $18.8 million in cash and cash equivalents. The company anticipates second-quarter revenue in the range of $1.3 million - $1.5 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017023033652/0000950170-23-033652-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.